Advancements in the field of spine and orthopedics are being made every day, and a number of game-changing procedures are ...
The growth of the endoscopic spinal surgery market is driven by increase in minimally invasive procedures, rise in spinal disorders, technological advancements, improved patient outcomes, and growth ...
The global endoscopic ultrasonography market, valued at US$1.28 billion in 2023, is forecasted to grow at a robust CAGR of ...
The Food and Drug Administration (FDA) has approved Tremfya ® (guselkumab) for the treatment of adults with moderately to severely active Crohn disease (CD).
HORSHAM, PA — Johnson & Johnson (NYSE: JNJ) has announced that the U.S. Food and Drug Administration (FDA) has approved ...
As many spine procedures become more minimally invasive, they’re also in a good position to grow in the ASC setting. Ask Spine Surgeons is a weekly series of questions posed to spine surgeons around ...
Pharmaceutical Technology on MSN3d
FDA approves Johnson & Johnson’s Tremfya to treat Crohn’s disease"FDA approves Johnson & Johnson’s Tremfya to treat Crohn’s disease" was originally created and published by Pharmaceutical ...
SAN DIEGO--(BUSINESS WIRE)--LivsMed, a leader in minimally invasive surgical devices, will unveil its ArtiSeal™ Vessel ...
World Effectiveness and Safety of Upadacitinib in Crohn’s Disease: A Multi-Centre Study," published in the March 2025 issue ...
The UBE-BONSS is widely known for its effectiveness in minimally invasive spinal surgeries, which typically cost over Rs 5 ...
The FDA has approved guselkumab (Tremfya) as the first IL-23 inhibitor offering both subcutaneous and intravenous induction ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback